Oncolytic viruses for the treatment of malignant glioma
Malignant glioma is the most common primary malignancy of the human CNS. Despite decades of research, the current therapeutic strategy consists of a multimodal regimen of surgery, chemotherapy and radiation. This course of therapy yields a median survival after diagnosis of ∼ 1 year. This dismal prognosis inspires the ongoing development of novel oncolytic agents targeting glioma, which include gene therapy, immunomodulatory therapy and oncolytic viruses. Oncolytic viruses are defined by their ability to target, replicate in and lyse tumour cells without critically damaging surrounding non-cancerous tissue. Although some viruses are naturally oncolytic and tumour-selective, the advent of modern recombinant DNA technology has allowed the engineering of additional viruses with improved therapeutic indices. This technological advance has enabled rapid growth in the field of viral therapy. Reovirus, Newcastle disease virus (NDV), measles virus, adenovirus, poliovirus and herpes simplex virus-1 are in preclinical and clinical development for use as oncolytic agents against malignant glioma. This report will focus on the recent patent literature in the field of oncolytic viruses for the treatment of malignant glioma. © 2006 Ashley Publications.
Merrill, MK; Selznick, LA; Gromeier, M
Volume / Issue
Start / End Page
International Standard Serial Number (ISSN)
Digital Object Identifier (DOI)